UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 432

Sortiert nach

Longitudinal Analysis of Neural Network Development in Preterm Infants

Cerebral cortex (New York, N.Y. 1991), 2010-12, Vol.20 (12), p.2852-2862

2010

Volltextzugriff (PDF)

Small Molecules That Reactivate p53 in Renal Cell Carcinoma Reveal a NF-κB-Dependent Mechanism of p53 Suppression in Tumors

Proceedings of the National Academy of Sciences - PNAS, 2005-11, Vol.102 (48), p.17448-17453

2005

Volltextzugriff (PDF)

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

Cancer medicine (Malden, MA), 2021-02, Vol.10 (3), p.797-805

2021

Volltextzugriff (PDF)

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

Proceedings of the National Academy of Sciences - PNAS, 2007-06, Vol.104 (25), p.10607-10612

2007

Volltextzugriff (PDF)

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

Blood advances, 2022-04, Vol.6 (7), p.2144-2155

2022

Volltextzugriff (PDF)

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism

Cancer research (Chicago, Ill.), 2004-03, Vol.64 (6), p.1951-1958

2004

Volltextzugriff (PDF)

The role of MRI in understanding the underlying mechanisms in obesity associated diseases

Biochimica et biophysica acta. Molecular basis of disease, 2017-05, Vol.1863 (5), p.1115-1131

2017

Volltextzugriff (PDF)

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

Journal of clinical oncology, 2023-09, Vol.41 (26), p.JCO2202721-4246

2023

Volltextzugriff (PDF)

PCR-Based Subtractive Hybridization and Differences in Gene Content among Strains of Helicobacter pylori

Proceedings of the National Academy of Sciences - PNAS, 1998-10, Vol.95 (22), p.13108-13113

1998

Volltextzugriff (PDF)

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Blood advances, 2020-02, Vol.4 (3), p.514-524

2020

Volltextzugriff (PDF)

Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response

Journal of Virology, 2005-09, Vol.79 (17), p.11105-11114

2005

Volltextzugriff (PDF)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

Blood, 2022-10, Vol.140 (17), p.1845-1857

2022

Volltextzugriff (PDF)

Stress-induced secretion of growth inhibitors : a novel tumor suppressor function of p53

Oncogene, 1998-09, Vol.17 (9), p.1089-1096

1998

Volltextzugriff (PDF)

Lisette Model's Explanation: Ralph Steiner, PM, and the Journalistic Frame

Oxford art journal, 2015-03, Vol.38 (1), p.95-115

Hill, J. E.

2015

Volltextzugriff (PDF)

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice

Cancer research (Chicago, Ill.), 2006-10, Vol.66 (19), p.9356-9361

2006

Volltextzugriff (PDF)

Training a sensibility : notes on American art and mass media

American art, 2013-06, Vol.27, p.2-9

2013

Volltextzugriff (PDF)

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial

Blood, 2021-11, Vol.138 (Supplement 1), p.3445-3445

2021

Volltextzugriff (PDF)

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Blood, 2021-11, Vol.138 (Supplement 1), p.2315-2315

2021

Volltextzugriff (PDF)

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

Blood, 2022-10, Vol.140 (17), p.1845-1857

2022

Volltextzugriff (PDF)

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Blood, 2020-11, Vol.136 (Supplement 1), p.16-17

2020

Volltextzugriff (PDF)

Lisette Model's Explanation: Ralph Steiner, TM, and the Journalistic Frame

Oxford art journal, 2015-01, Vol.38 (1), p.95-115

Hill, Jason E.

2015

Volltextzugriff (PDF)

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Blood, 2021-11, Vol.138 (Supplement 1), p.700-700

2021

Volltextzugriff (PDF)

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Blood, 2019-11, Vol.134 (Supplement_1), p.14-14

2019

Volltextzugriff (PDF)

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

Blood, 2018-11, Vol.132 (Supplement 1), p.1458-1458

2018

Volltextzugriff (PDF)

AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Clinical lymphoma, myeloma and leukemia, 2022-10, Vol.22, p.S230

2022

Volltextzugriff (PDF)

1 – 25 von 432

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(402)
Mit Volltextzugriff
(383)

Publikationsform

Sprache

Japanisch
(68)
Französisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(278)
Life Sciences & Biomedicine
(209)
Humans
(166)
Female
(70)
Male
(68)
Animals
(64)
Adult
(41)
Middle Aged
(41)
Biological And Medical Sciences
(40)
Science & Technology - Other Topics
(39)
Multidisciplinary Sciences
(36)
Medical Sciences
(31)
Aged
(30)
Mice
(30)
Physical Sciences
(30)
Patients
(28)
General & Internal Medicine
(27)
Genomes
(22)
Treatment Outcome
(22)
Adolescent
(21)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Longitudinal Analysis of Neural Network Development in Preterm Infants

Small Molecules That Reactivate p53 in Renal Cell Carcinoma Reveal a NF-κB-Dependent Mechanism of p53 Suppression in Tumors

The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloid leukemia

Activation of AMP-activated protein kinase by human EGF receptor 2/EGF receptor tyrosine kinase inhibitor protects cardiac cells

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

p53 pathway in renal cell carcinoma is repressed by a dominant mechanism

The role of MRI in understanding the underlying mechanisms in obesity associated diseases

Gilteritinib in Combination With Induction and Consolidation Chemotherapy and as Maintenance Therapy: A Phase IB Study in Patients With Newly Diagnosed AML

PCR-Based Subtractive Hybridization and Differences in Gene Content among Strains of Helicobacter pylori

Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Down-Regulation of p53 by Double-Stranded RNA Modulates the Antiviral Response

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3mut+ AML ineligible for intensive chemotherapy

Stress-induced secretion of growth inhibitors : a novel tumor suppressor function of p53

Lisette Model's Explanation: Ralph Steiner, PM, and the Journalistic Frame

Inhibition of p53 response in tumor stroma improves efficacy of anticancer treatment by increasing antiangiogenic effects of chemotherapy and radiotherapy in mice

Training a sensibility : notes on American art and mass media

Impact of FLT3 Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial

A Phase 1, Dose-Escalation Study of Gilteritinib Combined with Chemotherapy in Patients Aged 6 Months to <21 Years with FLT3 Internal Tandem Duplication-Positive Relapsed or Refractory AML

Phase 3 trial of gilteritinib plus azacitidine vs azacitidine for newly diagnosed FLT3 mut+ AML ineligible for intensive chemotherapy

A Phase 1 Study of Gilteritinib in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed AML: Final Results

Lisette Model's Explanation: Ralph Steiner, TM, and the Journalistic Frame

Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy

Emerging Mutations at Relapse in Patients with FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia Who Received Gilteritinib Therapy in the Phase 3 Admiral Trial

Impact of Minimal Residual Disease and Achievement of Complete Remission/Complete Remission with Partial Hematologic Recovery (CR/CRh) on Overall Survival Following Treatment with Gilteritinib in Patients with Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) with FLT3 Mutations

AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results

Aktive Filter

Suchergebnisse filtern